Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/CIMA-AEMPS/SUNITINIB CIPLA 50 MG CAPSULAS DURAS EFG

Approved

STANDARD

SUNITINIB CIPLA 50 MG CAPSULAS DURAS EFG

Cipla Europe🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Dec 21, 2020
Approval ID: 8622d97196866fd3
Company: Cipla Europe
Type: Standard

Approval Details

Approval Id: 8622d97196866fd3
Drug Cima Aemps Name: SUNITINIB CIPLA 50 MG CAPSULAS DURAS EFG
Register Number: 85668
Holder Company Name: Cipla Europe
Marketing Company Name: Cipla Europe Nv Sucursal En Espana
Authorization Date: 2020-12-21
Dosage Form: CÁPSULA DURA
Dose: 50 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: No
Company Name: Cipla Europe

Active Ingredients

SUNITINIB MALATO

66,8 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Dec 21, 2020

Approval ID

8622d97196866fd3

Type

Standard

Back to CIMA-AEMPS Approvals

SUNITINIB CIPLA 50 MG CAPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details